Thrombin generation and cell-dependent hypercoagulability in sickle cell disease
- PMID: 27430959
- DOI: 10.1111/jth.13416
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease
Abstract
Essentials Sickle cell disease is increasingly being recognized as a chronic hypercoagulable state. Thrombin generation is elevated in the whole blood, but not the plasma of sickle cell patients. Whole blood thrombin generation inversely correlates to erythrocyte phosphatidylserine exposure. Acquired protein S deficiency is likely explained by binding of protein S to sickle red cells. Click to hear Dr Hillery discuss coagulation and vascular pathologies in mouse models of sickle cell disease.
Summary: Introduction Sickle cell disease (SCD) is a hypercoagulable state with chronic activation of coagulation and an increased incidence of thromboembolic events. However, although plasma pre-thrombotic markers such as thrombin-anithrombin complexes and D-dimer are elevated, there is no consensus on whether global assays of thrombin generation in plasma are abnormal in patients with SCD. Based on our recent observation that normal red blood cells (RBCs) contribute to thrombin generation in whole blood, we hypothesized that the cellular components in blood (notably phosphatidylserine-expressing erythrocytes) contribute to enhanced thrombin generation in SCD. Methods Whole blood and plasma thrombin generation assays were performed on blood samples from 25 SCD patients in a non-crisis 'steady state' and 25 healthy race-matched controls. Results Whole blood thrombin generation was significantly elevated in SCD, whereas plasma thrombin generation was paradoxically reduced compared with controls. Surprisingly, whole blood and plasma thrombin generation were both negatively correlated with phosphatidylserine exposure on RBCs. Plasma thrombin generation in the presence of exogenous activated protein C or soluble thrombomodulin revealed deficiencies in the protein C/S anticoagulant pathway in SCD. These global changes were associated with significantly lower plasma protein S activity in SCD that correlated inversely with RBC phosphatidylserine exposure. Conclusion Increased RBC phosphatidylserine exposure in SCD is associated with acquired protein S deficiency. In addition, these data suggest a cellular contribution to thrombin generation in SCD (other than RBC phosphatidylserine exposure) that explains the elevated thrombin generation in whole blood.
Keywords: anemia; erythrocyte; phosphatidylserine; protein S; sickle cell; thrombin.
© 2016 International Society on Thrombosis and Haemostasis.
Similar articles
-
Folate supplementation in people with sickle cell disease.Cochrane Database Syst Rev. 2018 Mar 16;3(3):CD011130. doi: 10.1002/14651858.CD011130.pub3. Cochrane Database Syst Rev. 2018. PMID: 29546732 Free PMC article.
-
Hydroxyurea (hydroxycarbamide) for sickle cell disease.Cochrane Database Syst Rev. 2017 Apr 20;4(4):CD002202. doi: 10.1002/14651858.CD002202.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2022 Sep 1;9:CD002202. doi: 10.1002/14651858.CD002202.pub3. PMID: 28426137 Free PMC article. Updated.
-
Preoperative blood transfusions for sickle cell disease.Cochrane Database Syst Rev. 2016 Apr 6;4(4):CD003149. doi: 10.1002/14651858.CD003149.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Jul 2;7:CD003149. doi: 10.1002/14651858.CD003149.pub4. PMID: 27049331 Free PMC article. Updated.
-
Hydroxyurea (hydroxycarbamide) for sickle cell disease.Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3. Cochrane Database Syst Rev. 2022. PMID: 36047926 Free PMC article.
-
Interventions for chronic kidney disease in people with sickle cell disease.Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD012380. doi: 10.1002/14651858.CD012380.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Aug 4;8:CD012380. doi: 10.1002/14651858.CD012380.pub3. PMID: 28672087 Free PMC article. Updated.
Cited by
-
Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening.FASEB J. 2022 Jun;36(6):e22360. doi: 10.1096/fj.202100809RR. FASEB J. 2022. PMID: 35593742 Free PMC article.
-
COVID-19 Infection and Acute Pulmonary Embolism in an Adolescent Female With Sickle Cell Disease.Cureus. 2020 Dec 28;12(12):e12348. doi: 10.7759/cureus.12348. Cureus. 2020. PMID: 33520543 Free PMC article.
-
Therapeutic strategies for sickle cell disease: towards a multi-agent approach.Nat Rev Drug Discov. 2019 Feb;18(2):139-158. doi: 10.1038/s41573-018-0003-2. Nat Rev Drug Discov. 2019. PMID: 30514970 Free PMC article. Review.
-
Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit.Toxins (Basel). 2019 Nov 13;11(11):660. doi: 10.3390/toxins11110660. Toxins (Basel). 2019. PMID: 31766155 Free PMC article. Review.
-
COVID-19 and Sickle Cell Disease: Two Independent Risk Factors for Venous Thromboembolism.Cureus. 2023 Apr 6;15(4):e37226. doi: 10.7759/cureus.37226. eCollection 2023 Apr. Cureus. 2023. PMID: 37159776 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical